



(12) Translation of
European patent specification

(11) NO/EP 3402503 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 38/00 (2006.01) A61K 31/522 (2006.01)
A61K 31/454 (2006.01) A61K 39/00 (2006.01)
A61K 31/4985 (2006.01) A61K 45/06 (2006.01)
A61K 31/517 (2006.01) A61P 19/02 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)
A61K 31/52 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.02.22

(80) Date of The European
Patent Office Publication of
the Granted Patent 2020.10.21

(86) European Application Nr. 17701596.3

(86) European Filing Date 2017.01.13

(87) The European Application's
Publication Date 2018.11.21

(30) Priority 2016.01.13, US, 201662278374 P
2016.08.05, US, 201662371626 P

(84) Designated Contracting
States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;
IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;
SK ; SM ; TR

Designated Extension
States: BA ; ME

(73) Proprietor Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, Nederland

(72) Inventor KAPTEIN, Allard, Marten van Rossemsingel 51, 5301 HB Zaltbommel, Nederland
ROTHBAUM, Wayne, 1171 S. Ocean Boulevard, Delray Beach, Florida 33483, USA
LANNUTTI, Brian, 627 Glencrest Place, Solana Beach, California 92075, USA

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR**

(56) References

Cited: EP-A1- 2 786 996, WO-A1-2013/010868, WO-A1-2015/061752, WO-A2-2015/110923,
US-A1- 2014 256 734
GIORGIO V SCAGLIOTTI ET AL: "Antimetabolites and cancer: emerging data with a focus on
antifolates", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 16, no. 2, 1 February 2006
(2006-02-01), pages 189-200, XP055141364, ISSN: 1354 -3776, DOI:
10.1517/13543776.16.2.189
AstraZeneca: "Majority -stake investment in Acerta Pharma", astrazeneca.com , 17 December
2015 (2015-12-17), XP002768715, Retrieved from the Internet:
URL:https://www.astrazeneca.com/content/dam/az/PDF/Acerta_Investor_conference_call_1
7_December_2015.pdf [retrieved on 2016-03-27]

D. XU ET AL: "RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 341, no. 1, 6 January 2012 (2012-01-06), pages 90-103, XP055227121, DOI: 10.1124/jpet.111.187740


Clinical trials: "A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate", clinicaltrials.gov , 4 November 2015 (2015-11-04), XP002768714, Retrieved from the Internet: URL:[https://clinicaltrials.gov/archive/NCT 02387762/2015_11_04](https://clinicaltrials.gov/archive/NCT_02387762/2015_11_04) [retrieved on 2016-03-27]

DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002764066, retrieved from REGISTRY; STN Database accession no. 1420477-60-6

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** En kombinasjon, som omfatter en BTK-inhibitor som har en struktur med formel (Formula) (2):




eller et farmasøytisk akseptabelt salt derav, og metotreksat eller et farmasøytisk akseptabelt salt derav for bruk ved behandling av revmatoid artritt.

10

- 2.** En sammensetning, som omfatter terapeutisk effektive mengder av:

(1) en BTK-inhibitor som har en struktur med formel (2):




15

eller et farmasøytisk akseptabelt salt derav, og

(2) metotreksat eller et farmasøytisk akseptabelt salt derav,
for bruk ved behandling av revmatoid artritt.

3. Et sett, bestående av:

- 5 en farmasøytisk sammensetning, som omfatter en BTK-inhibitor som har en struktur med formel (2):



eller et farmasøytisk akseptabelt salt derav, og

- 10 en farmasøytisk sammensetning, som omfatter metotreksat eller et farmasøytisk akseptabelt salt derav,

for co-administrering av nevnte metotreksat og forbindelsen med formel (2),
enten samtidig eller separat,

for bruk ved behandling av revmatoid artritt.